FibroGen Collaborates with Regeneron to Assess FG-3165 and FG-3175 Plus Libtayo for Treating Solid Tumors
Shots:
- FibroGen and Regeneron have entered into a clinical trial supply agreement to conduct a clinical evaluation of FibroGen’s FG-3165 (galectin-9 targeting Ab) and FG-3175 (c-c motif chemokine receptor 8 targeting Ab), in addition to Libtayo for treating solid tumors
- As per the agreement, FibroGen will be responsible for conducting P-I monotx. and combination studies with Regeneron supplying Libtayo for the same. The companies will keep the rights of their compounds both as monotx. and combination
- Furthermore, the IND application of FG-3165 for solid tumors has been cleared by the US FDA today with its P-I study anticipated in H2’24. The IND application for FG-3175 is expected in 2025
Ref: Fibrogen | Image: Fibrogen
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
